KRAS and lung carcinoma: The KRAS G12C inhibitor known as JNJ-74699157 is currently being tested in a phase I clinical trial to determine the tolerated dose in patients with advanced solid tumors, including lung cancer (Clinicaltrials.gov Identifier: NCT04006301 (accessed on 24 February 2021)).